07 Jan, 2024 Final Analysis of the Taiwan Cohort of the ENVISION Study of Givosiran Published in the Journal of the Formosan Medical Association
Posted at 15:49h
in Capella
Results from a subgroup analysis of the Phase 3 ENVISION study examining the long-term (up to 36 months) efficacy and safety of givosiran in Taiwanese patients with acute hepatic porphyria (AHP) were published in the Journal of the Formosan Medical Association.
